MK 966
Categorie
MK 966 Les marques, MK 966 Analogs
MK 966 Les marques melange
MK 966 Formule chimique
C17H14O4S
MK 966 RX lien
http://www.rxlist.com/cgi/generic/rofecox.htm
MK 966 FDA fiche
MK 966 msds (fiche de securite des materiaux)
MK 966 Synthese de reference
Aucune information disponible
MK 966 Poids moleculaire
314.357 g/mol
MK 966 Point de fusion
No information avaliable
MK 966 H2O Solubilite
Insolubles
MK 966 Etat
Solid
MK 966 LogP
3.019
MK 966 Formes pharmaceutiques
Tablet (12,5 mg, 25 mg ou 50 mg); suspension buvable (12,5 ou 25 mg par 5 ml de solution)
MK 966 Indication
Pour le traitement de l'arthrose, la douleur aiguë chez les adultes et les douleurs menstruelles.
MK 966 Pharmacologie
Le rofécoxib, un cyclo-oxygénase-2 sélectifs (COX-2) inhibiteur, est classé comme un anti-inflammatoire non stéroïdien (AINS). Le rofécoxib est utilisé pour ses activités anti-inflammatoires, analgésiques et antipyrétiques dans la gestion de l'ostéoarthrite (OA) et pour le traitement de la dysménorrhée ou douleur aiguë. Contrairement célécoxib, le rofécoxib n'a pas de chaîne de sulfamides et ne nécessite pas les enzymes CYP450 pour le métabolisme.
MK 966 Absorption
La biodisponibilité orale moyenne du rofécoxib à des doses thérapeutiquement recommandée de 12,5, 25 et 50 mg est d'environ 93%.
MK 966 Toxicite
Aucun cas de surdosage ont été signalés pendant le rofécoxib essais cliniques. L'administration de doses uniques de rofécoxib 1000 mg à 6 volontaires sains et de doses multiples de 250 mg / jour pendant 14 jours à 75 volontaires sains n'a pas entraîné de toxicité grave.
MK 966 Information pour les patients
PATIENT INFORMATION
Physicians should instruct their patients to read the patient package insert before starting therapy with VIOXX and to reread
it each time the prescription is renewed in case any information has changed.
VIOXX can cause discomfort and, rarely, more serious side effects, such as gastrointestinal bleeding, which may result in
hospitalization and even fatal outcomes. Although serious GI tract ulcerations and bleeding can occur without warning symptoms,
patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing
any indicative signs or symptoms. Patients should be apprised of the importance of this follow-up. Risk of GI Ulceration, Bleeding
and Perforation. Patients should be informed that VIOXX is not a substitute for aspirin for cardiovascular prophylaxis because of
its lack of effect on platelets. For additional cardiovascular safety information see CLINICAL STUDIES, Special Studies, VIGOR and
PRECAUTIONS, Cardiovascular Effects.
Patients should promptly report signs or symptoms of gastrointestinal ulceration or bleeding, skin rash, unexplained weight gain,
edema or chest pain to their physicians.
Physicians should instruct their patients to read the patient package insert before starting therapy with VIOXX and to reread
it each time the prescription is renewed in case any information has changed.
VIOXX can cause discomfort and, rarely, more serious side effects, such as gastrointestinal bleeding, which may result in
hospitalization and even fatal outcomes. Although serious GI tract ulcerations and bleeding can occur without warning symptoms,
patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing
any indicative signs or symptoms. Patients should be apprised of the importance of this follow-up. Risk of GI Ulceration, Bleeding
and Perforation. Patients should be informed that VIOXX is not a substitute for aspirin for cardiovascular prophylaxis because of
its lack of effect on platelets. For additional cardiovascular safety information see CLINICAL STUDIES, Special Studies, VIGOR and
PRECAUTIONS, Cardiovascular Effects.
Patients should promptly report signs or symptoms of gastrointestinal ulceration or bleeding, skin rash, unexplained weight gain,
edema or chest pain to their physicians.
MK 966 Organismes affectes
Les humains et autres mammifères
